Neurologic Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 52: | Line 52: | ||
==== 6. Myelosuppression ==== | ==== 6. Myelosuppression ==== | ||
==COVID-19 Experimental Treatments with Interaction Potential== | ==COVID-19 Experimental Treatments with Interaction Potential== | ||
===1. [[Remdesivir]] (GS‐5734)=== | ===1. [[Remdesivir]] (GS‐5734)=== | ||
| Line 97: | Line 74: | ||
*Concurrent use with [[Hydroxychloroquine|hydroxychloroquine-]] decreases the antiviral activity of [[Remdesivir|remdesivir.]] | *Concurrent use with [[Hydroxychloroquine|hydroxychloroquine-]] decreases the antiviral activity of [[Remdesivir|remdesivir.]] | ||
===2. [[Lopinavir/ Ritonavir (Kaltera)]] (400 mg/100 mg)=== | ===2. [[Lopinavir and Ritonavir|Lopinavir/ Ritonavir (Kaltera)]] (400 mg/100 mg)=== | ||
=====Pharmacokinetics and Dosing:===== | =====Pharmacokinetics and Dosing:===== | ||
| Line 130: | Line 107: | ||
*Rare reports of [[Second degree AV block|2nd and 3rd-degree atrioventricular block]] in patients with underlying risk factors | *Rare reports of [[Second degree AV block|2nd and 3rd-degree atrioventricular block]] in patients with underlying risk factors | ||
===3. [[Chloroquine|Chloroquin]]<nowiki/>e/[[Hydroxychloroquine]]=== | ===3. [[Chloroquine|Chloroquin]]<nowiki/>[[Chloroquine|e]]/[[Hydroxychloroquine]]=== | ||
=====Pharmacokinetics and Dosing:===== | =====Pharmacokinetics and Dosing:===== | ||
| Line 179: | Line 156: | ||
*Can interfere with [[azathioprine]] metabolism possibly leading to accumulation of [[6‐methylthioinosine monophosphate]] [[6-MTIMP|(6‐MTIMP]]), which has been associated with [[myelotoxicity]] | *Can interfere with [[azathioprine]] metabolism possibly leading to accumulation of [[6‐methylthioinosine monophosphate]] [[6-MTIMP|(6‐MTIMP]]), which has been associated with [[myelotoxicity]] | ||
===6. [[Favipiravir]]=== | ===6. [[Favipiravir covid-19|Favipiravir]]=== | ||
=====Pharmacokinetics and Dosing:===== | =====Pharmacokinetics and Dosing:===== | ||
=====Chinese Clinical Trials Registry ID:===== | =====Chinese Clinical Trials Registry ID:===== | ||
| Line 227: | Line 204: | ||
*Will compete for binding sites; monitor drugs highly protein-bound with a narrow [[therapeutic index]] (such as warfarin) | *Will compete for binding sites; monitor drugs highly protein-bound with a narrow [[therapeutic index]] (such as warfarin) | ||
===9. Tocilizumab (IL‐6 monoclonal antibody)=== | ===9. [[Tocilizumab]] [[(IL‐6 monoclonal antibody]])=== | ||
====Pharmacokinetics and Dosing:==== | ====Pharmacokinetics and Dosing:==== | ||
=====ClinicalTrials.gov Identifier:===== | =====ClinicalTrials.gov Identifier:===== | ||
| Line 237: | Line 214: | ||
*Nil significant drug interactions. | *Nil significant drug interactions. | ||
*COVID‐19 increases IL‐6 expression. Tocilizumab reduces IL‐6 expression. IL‐6 increases CYP3A4, CYP26C19, CYP2C9, CYP1A2. When tocilizumab is used to treat COVID‐19, the effect on drugs affected by these CYP enzymes is unknown. | *COVID‐19 increases IL‐6 expression. [[Tocilizumab]] reduces IL‐6 expression. IL‐6 increases [[CYP 3A4|CYP3A4,]] [[CYP26C19]], [[CYP2C9]], [[CYP1A2]]. When [[tocilizumab]] is used to treat COVID‐19, the effect on drugs affected by these [[CYP]] enzymes is unknown. | ||
=== 10. Dexamthasone === | === 10. [[Dexamethasone|Dexamthasone]]=== | ||
==== Pharmacokinetics and Dosing: ==== | ==== Pharmacokinetics and Dosing: ==== | ||
* Oral or Intravenous- 6mg/day for 10 days | * Oral or [[Intravenous]]- 6mg/day for 10 days | ||
* Given in patients who are mechanically ventilated. | * Given in patients who are [[Mechanical ventilation|mechanically ventilated.]] | ||
===== Clinical Trial: ===== | ===== Clinical Trial: ===== | ||
| Line 252: | Line 229: | ||
===== Interaction Potential: ===== | ===== Interaction Potential: ===== | ||
* Interacts with many drugs like | * Interacts with many drugs like [[oral contraceptive pills]], [[digoxin]], [[blood thinners]] ( [[clopidogrel]], [[Warfarin|warfarin,]] [[dabigatran]] ) | ||
=== 11. Ivermectin: === | === 11. [[Ivermectin]]: === | ||
* It is not FDA approved for use in SARS-CoV2 | * It is not FDA approved for use in SARS-CoV2 | ||
| Line 260: | Line 237: | ||
==== Pharmacokinetics: ==== | ==== Pharmacokinetics: ==== | ||
* Metabolised by | * Metabolised by [[Microsome|liver microsomes]] by [[Cytochrome P450|Cyt P450-3A4]] | ||
==== Research Trial: ==== | ==== Research Trial: ==== | ||
| Line 268: | Line 245: | ||
==== Interactions: ==== | ==== Interactions: ==== | ||
* Ivermectin increases the side effects of blood thinners. | *[[Ivermectin]] increases the side effects of [[blood thinners]]. | ||
* Grapefruit juice increases the concentration of Ivermectin. | *[[Grapefruit juice]] increases the concentration of [[Ivermectin|ivermectin.]] | ||
*Avoid or limit | *Avoid or limit [[alcohol]] use in patients taking [[ivermectin]]. | ||
==References== | ==References== | ||
Latest revision as of 02:28, 11 July 2020
To go to the COVID-19 project topics list, click here.
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neurologic Disorders and COVID-19 On the Web |
|
American Roentgen Ray Society Images of Neurologic Disorders and COVID-19 |
|
Risk calculators and risk factors for Neurologic Disorders and COVID-19 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ;Fahimeh Shojaei, M.D.;Niloofarsadaat Eshaghhosseiny, MD[2];Rinky Agnes Botleroo, M.B.B.S.
Overview
Pathophysiology of the Complications in the Nervous System
Mechanism of targetting the Nervous System
Complications in the Central Nervous System
Cerebrovascular Accident/Stroke
- Hemorrhagic
- Ischaemic
Acute Encephalitis
Viral Meningitis
Epileptic Seizures
Encephalopathy
Headache
Complications in the Peripheral Nervous system
Guillain-Barre syndrome
Anosmia
Acute Myelitis
Miller Fischer Sydrome
Polyneuritis Cranialis
Complications due to medication interaction
1. Statin induced myotoxicity
2. 2nd and 3rd degree atrioventricular block
3. Prolong QTc interval
4. Myelotoxicity
5. Prolonged PR interval
6. Myelosuppression
COVID-19 Experimental Treatments with Interaction Potential
1. Remdesivir (GS‐5734)
Pharmacokinetics and Dosing:
- Adults ≥40 kg: Daily IV dose over 30 min.
Day 1: 200 mg, Day 2‐10: 100 mg
- Paed <40 kg: Daily IV dose over 30 min. Day 1: 5 mg/kg, Day 2‐10: 2.5 mg/kg
ClinicalTrials.gov Identifier:
- NCT04302766
- NCT04292899
Interaction Potential:
- Inhibits: CYP3A4, OATP1B1/3, BSEP, MRP4, and NTCP
- Induces: CYP1A2 and CYP2B6
- Unlikely clinically significant (all in vitro data)
- Concurrent use with hydroxychloroquine- decreases the antiviral activity of remdesivir.
Pharmacokinetics and Dosing:
- 400mg/100mg twice daily for 14 days
- Crushing tablet ↓ absorption ≅ 45%133.
- Use oral liquid (42.4% alcohol and 15.3% propylene glycol)
- Use compatible feeding tubes (PVC or silicone)
- Avoid metronidazole and disulfiram
- Absorbed in jejunum: NG ok; NJ may ↓ effect
ClinicalTrials.gov Identifier:
- NCT04276688
Chinese Clinical Trials Registry ID:
- ChiCTR2000029539
EU Clinical Trials Register ID:
- 2020‐000936‐23
Interaction Potential:
- Lopinavir extensively metabolized by CYP3A
- Inhibitor of CYP3A4 (potent), P‐gp, BCPR, and OATP1B1
- can increase concentration of drugs metabolized or substrates of these pathways
- Inducer of CYP2C9, CYP2C19, and glucuronidation
- Can prolong PR interval.
- Rare reports of 2nd and 3rd-degree atrioventricular block in patients with underlying risk factors
3. Chloroquine/Hydroxychloroquine
Pharmacokinetics and Dosing:
- 200 mg three times a day for 10 days
ClinicalTrials.gov Identifier:
- NCT04261517
Chinese Clinical Trials Registry ID:
- ChiCTR2000029609
Interaction Potential:
- Metabolised by CYP2C8, CYP3A4, CYP2D6
- Inhibited by CYP2D6 and P‐gp
- Can prolong QTc interval, consider ECG monitoring where appropriate
- Concurrent use of HCQS with antibiotic azithromycin causes chest pain, congestive heart failure.
- Antacids decrease the absorption of hydroxychloroquine.
- Neostigmine, pyridostigmine antagonize the action of hydroxychloroquine.
4. Interferon beta
Pharmacokinetics and Dosing:
ClinicalTrials.gov Identifier:
- NCT04276688
Interaction Potential:
- Interferons have been reported to reduce CYP450 drug metabolism
- Care with narrow therapeutic index drugs dependent on CYP450 clearance
5. Ribavirin
Pharmacokinetics and Dosing:
- Do not crush – known teratogen.
- Contact hospital pharmacy for solution compounded from capsules or (SAS) product availability
ClinicalTrials.gov Identifier:
- NCT04276688
Interaction Potential:
- Not metabolized by CYP450 unlikely to contribute to CYP interactions.
- Inhibits inosine monophosphate dehydrogenase:
- Can interfere with azathioprine metabolism possibly leading to accumulation of 6‐methylthioinosine monophosphate (6‐MTIMP), which has been associated with myelotoxicity
6. Favipiravir
Pharmacokinetics and Dosing:
Chinese Clinical Trials Registry ID:
- ChiCTR2000029600 (favipiravir plus interferon‐α)
- ChiCTR2000029544 (favipiravir plus baloxavir marboxil)
Interaction Potential:
- Metabolised by aldehyde oxidase in the cytosol of the liver.
- Inhibits:
- CYP2C8 (strong)
- OAT1, OAT3 (mod)
- CYP1A2 (weak) , CYP2C9 (weak) , CYP2C19 (weak) , CYP2CD6 (weak) , CYP2E1 (weak) , CYP3A4 (weak)
- Aldehyde oxidase Inhibitors increase the concentration of favipiravir. The drugs include selective estrogen receptor modulators(SERMs), H2 receptor antagonists like cimetidine, calcium channel blockers, anti-arrythmic drugs like propafenone, tricyclic antidepressants.[1]
- Low-risk QT prolongation
Pharmacokinetics and Dosing:
- Requires pH <4.
- Avoid antacids 2 h before and 1 hour after.
- Food ↑ bioavailability
- Absorbed in jejunum: NG ok; NJ may ↓ effect
ClinicalTrials.gov Identifier:
Interaction Potential:
- Metabolised by: CYP3A4 (extensively)
- Inhibits: CYP3A4, UGT1A1, OATP1B1 (strong), CYP2C8 (weak)
- Absorption depends on low pH; drugs increasing pH will decrease atazanavir concentration
- Dose-related prolongation in PR interval.
- Care with drugs increasing QT interval or in patients with pre‐existing risk factors.
8. Nitazoxanide (prodrug) (active metabolite: tizoxanide)
Pharmacokinetics and Dosing:
- Maybe dispersible or crushed– check the brand
- Take with food ‐ increases bioavailability by 50%.
ClinicalTrials.gov Identifier:
Interaction Potential:
- Nil effects on CYP450 enzymes
- Tizoxanide highly protein-bound (>99.9%)
- Will compete for binding sites; monitor drugs highly protein-bound with a narrow therapeutic index (such as warfarin)
9. Tocilizumab (IL‐6 monoclonal antibody)
Pharmacokinetics and Dosing:
ClinicalTrials.gov Identifier:
- NCT04310228
- NCT04306705
Interaction Potential:
- Nil significant drug interactions.
- COVID‐19 increases IL‐6 expression. Tocilizumab reduces IL‐6 expression. IL‐6 increases CYP3A4, CYP26C19, CYP2C9, CYP1A2. When tocilizumab is used to treat COVID‐19, the effect on drugs affected by these CYP enzymes is unknown.
10. Dexamthasone
Pharmacokinetics and Dosing:
- Oral or Intravenous- 6mg/day for 10 days
- Given in patients who are mechanically ventilated.
Clinical Trial:
- Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial
Interaction Potential:
- Interacts with many drugs like oral contraceptive pills, digoxin, blood thinners ( clopidogrel, warfarin, dabigatran )
11. Ivermectin:
- It is not FDA approved for use in SARS-CoV2
Pharmacokinetics:
- Metabolised by liver microsomes by Cyt P450-3A4
Research Trial:
- A study by a National Breast Cancer Foundation Fellowship, Australia (ECF-17-007) for KMW and an National Health and Medical Research Council (NHMRC), Australia Senior Prinicple Research Fellow (SPRF) (APP1103050) for DAJ, found Ivermectin to be effective in treating SARs-CoV2.[2][3]
Interactions:
- Ivermectin increases the side effects of blood thinners.
- Grapefruit juice increases the concentration of ivermectin.
- Avoid or limit alcohol use in patients taking ivermectin.
References
- ↑ Obach, R. Scott; Huynh, Phuong; Allen, Mary C.; Beedham, Christine (2004). "Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs". The Journal of Clinical Pharmacology. 44 (1): 7–19. doi:10.1177/0091270003260336. ISSN 0091-2700.
- ↑ Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020). "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro". Antiviral Res. 178: 104787. doi:10.1016/j.antiviral.2020.104787. PMC 7129059 Check
|pmc=value (help). PMID 32251768 Check|pmid=value (help). - ↑ Rizzo, Emanuele (2020). "Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action". Naunyn-Schmiedeberg's Archives of Pharmacology. 393 (7): 1153–1156. doi:10.1007/s00210-020-01902-5. ISSN 0028-1298.